Summit Therapeutics
SMMT
17.95
+0.64
+3.70%
Summit Therapeutics
US · SMMT
#1207 by market cap
Listed 2015
17.95
+0.64
+3.70%
Live - 5344 symbols - heartbeat 132s ago
· 2026-10-08 06:49
Pre-market
17.80
-0.84%
After-hours
17.97
+0.11%
Overnight
17.71
-1.34%
- Market cap
- 14.32B
- P/E (TTM)i
- -16.17
- P/Bi
- 22.72
- EPSi
- -1.44
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on SMMT?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 743.00K | 860.00K | 1.81M | 705.00K | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 11.28M | 19.20M | 23.60M | 26.74M | 29.26M | 60.20M | 556.70M |
| Research & development | -- | 34.34M | 53.27M | 85.35M | 52.00M | 59.47M | 150.78M | 537.67M |
| Operating profit | -- | -27.47M | -52.30M | -86.18M | -63.62M | -88.74M | -210.98M | -1.09B |
| Pretax profit | -- | -29.09M | -52.91M | -88.60M | -78.78M | -614.93M | -221.30M | -1.08B |
| Tax | -- | 36.00K | -213.00K | -- | -- | -- | -- | -- |
| Net profit | -- | -29.13M | -52.70M | -88.60M | -78.78M | -614.93M | -221.30M | -1.08B |
| Basic EPS | -- | -1 | -1 | -1 | 0 | -1 | 0 | -1 |
| Diluted EPS | -- | -0.89 | -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 15.59M | 360.42M | 103.12M | 77.58M | 62.59M | 62.76M |
| Research & development | 51.27M | 208.02M | 131.10M | 147.29M | 132.62M | 157.73M |
| Operating profit | -66.85M | -568.44M | -234.21M | -224.88M | -195.21M | -220.50M |
| Pretax profit | -62.91M | -565.71M | -231.79M | -219.12M | -189.42M | -215.70M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -62.91M | -565.71M | -231.79M | -219.12M | -189.42M | -215.70M |
| Basic EPS | 0 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.09 | -0.76 | -0.31 | -0.29 | -0.24 | -0.28 |
Balance sheet
| Line item | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 79.63M | 87.67M | 97.31M | 656.71M | 189.71M | 423.75M | 720.30M |
| Cash & ST investments | -- | 63.84M | 66.42M | 71.79M | 348.61M | 186.24M | 412.35M | 713.45M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 96.25M | 102.50M | 113.37M | 664.17M | 202.95M | 435.56M | 751.18M |
| Total current liabilities | -- | 13.77M | 19.89M | 25.62M | 38.78M | 20.41M | 41.73M | 72.99M |
| Short-term debt | -- | 471.00K | 390.00K | 1.09M | 21.46M | 2.81M | 3.77M | 3.39M |
| Long-term debt | -- | -- | -- | -- | 494.54M | 100.00M | -- | -- |
| Total liabilities | -- | 17,385,000.00 | 23,045,000.00 | 30,090,000.00 | 537,514,000.00 | 125,257,000.00 | 46,812,000.00 | 92,322,000.00 |
| Total equity | -- | 78.86M | 79.45M | 83.28M | 126.65M | 77.69M | 388.75M | 658.86M |
| Retained earnings | -- | -163.01M | -210.95M | -299.55M | -378.33M | -993.26M | -1.21B | -2.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 370.75M | 309.24M | 246.47M | 720.30M | 616.60M | 720.58M |
| Cash & ST investments | 361.32M | 297.87M | 238.55M | 713.45M | 598.73M | 690.68M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 383.82M | 324.04M | 261.73M | 751.18M | 647.86M | 752.19M |
| Total current liabilities | 34.88M | 60.33M | 64.93M | 72.99M | 83.27M | 103.57M |
| Short-term debt | 3.54M | 3.12M | 2.72M | 3.39M | 3.18M | 3.55M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 39,492,000.00 | 64,598,000.00 | 69,466,000.00 | 92,322,000.00 | 101,924,000.00 | 122,202,000.00 |
| Total equity | 344.33M | 259.44M | 192.26M | 658.86M | 545.93M | 629.98M |
| Retained earnings | -1.28B | -1.84B | -2.07B | -2.29B | -2.48B | -2.70B |
Cash flow
| Line item | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -20.76M | -48.11M | -72.59M | -41.58M | -76.76M | -142.11M | -322.93M |
| Depreciation & amortization | -- | 1.64M | 2.00M | 2.46M | 1.26M | 198.00K | 89.00K | 146.00K |
| Free cash flow | -- | -21.10M | -48.53M | -72.89M | -42.21M | -76.89M | -142.25M | -323.59M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 50.42M | 50.00M | 75.00M | 100.00M | 109.69M | 477.89M | 604.57M |
| Ending cash balance | -- | 63.84M | 66.42M | 71.79M | 648.61M | 71.43M | 105.19M | 225.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -61.17M | -66.74M | -93.08M | -101.94M | -122.29M | -141.12M |
| Depreciation & amortization | 25.00K | 37.00K | 42.00K | 42.00K | 44.00K | 46.00K |
| Free cash flow | -61.59M | -66.74M | -93.15M | -102.10M | -122.54M | -142.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 31.76M | 572.80M | -- | -- |
| Ending cash balance | 211.84M | 298.19M | 238.88M | 225.58M | 106.83M | 419.68M |
Returns & efficiency
| Line item | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 28.30 | -- | -67.08 | -108.89 | -75.05 | -601.85 | -94.90 | -206.11 |
| ROA %i | 12.76 | -- | -53.13 | -82.09 | -20.26 | -141.83 | -69.32 | -181.94 |
| ROIC %i | 29.45 | -- | -66.20 | -106.42 | -20.34 | -146.86 | -78.00 | -200.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -189.45 | -217.36 |
| EBIT margin %i | 12.68 | -- | -6,122.67 | -4,882.31 | -10,550.50 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.56 | -- | 4.41 | 3.80 | 16.93 | 9.30 | 10.15 | 9.87 |
| Quick ratioi | 3.00 | -- | 4.33 | 3.75 | 9.15 | 9.17 | 9.88 | 9.77 |
| Debt / assetsi | 1.66 | -- | 0.45 | 2.45 | 78.11 | 52.28 | 1.66 | 2.78 |
| LT debt / equityi | 1.52 | -- | 0.09 | 2.03 | 392.65 | 132.95 | 0.89 | 2.66 |
| Interest coveragei | 12.87 | -- | -206.49 | -314.31 | -16.90 | -36.36 | -24.48 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -26.54 | -43.96 | -67.42 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -123.93 | -328.30 | -292.49 | -206.11 | -270.95 | -192.50 |
| ROA %i | -85.89 | -224.08 | -241.08 | -181.94 | -233.81 | -159.09 |
| ROIC %i | -93.23 | -261.48 | -275.89 | -200.72 | -263.12 | -187.05 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.63 | 5.13 | 3.80 | 9.87 | 7.41 | 6.96 |
| Quick ratioi | 10.36 | 4.94 | 3.67 | 9.77 | 7.19 | 6.67 |
| Debt / assetsi | 1.68 | 1.71 | 2.07 | 2.78 | 3.09 | 2.71 |
| LT debt / equityi | 0.84 | 0.94 | 1.41 | 2.66 | 3.09 | 2.67 |
| Interest coveragei | -42.26 | -301.90 | -102,397.89 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
Latin America100.00%
Quote time 2026-10-08 06:49:11 · For reference only, not investment advice and not tailored to your situation.